ImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer Center

ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the execution of a Memorandum of Understanding (MOU) with a premier NCI-designated Comprehensive Cancer Center in the United States, renowned globally for its pioneering history in cellular immunotherapy. This partnership will fast-track ImmunoScape’s “Seed and Boost” platform into the clinic. Concurrently, the company announced a strategic investment from Leonardo DiCaprio.